New Quantum Blue® Infliximab posters at UEGW Virtual 2020

BÜHLMANN presented two posters on the high quality of the Quantum Blue® Infliximab rapid test at this year’s virtual UEGW 2020.

First successful comparison of Quantum Blue® rapid TDM assay standardization with WHO international standard for infliximab

Recent results presented at UEG Week Virtual 2020 show an excellent correlation of the Quantum Blue® Infliximab standardization with the new WHO standard for infliximab (NIBSC 16/170) (Keller E. et al., 2020). The findings underline the reliability of the trough level rapid test and thus its importance for patient near therapeutic drug monitoring.

Quantum Blue® Infliximab highly correlates to the HPLC tandem mass spectrometry method at Mayo clinic

Lateral flow technology meets mass spectrometry. New data presented at UEG Week 2020 exhibits high correlation of the Quantum Blue® Infliximab rapid test to the gold standard HPLC tandem mass spectrometry method at Mayo clinic (USA) (Olson R.N. et al., 2020).